Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice

Cancer Letters

Volumn 287, Issue 1, 2010, Pages 75-81

  Zhou, Shuwen ^a   Kawakami, Shigeru ^a   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CpG DNA; Intranasal; Liposomes; Pulmonary metastasis

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; LIPOPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG DISTRIBUTION; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TISSUE DISTRIBUTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOKINES; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES;

MUS;

EID: 72049111258     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.05.037     Document Type: Article

References (28)

1. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
2. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6 (2006) 148-158
3. Krieg A.M. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117 (2007) 1184-1194
4. -A Kim H., Ko H.-M., Ju H.-W., Kim K.-J., Roh S.-G., Lee H.-K., and Im S.-Y. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells. Cancer Lett. 274 (2009) 160-164
5. Jahrsdorfer B., and Weiner G.J. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Therap. 3 (2008) 27-32
6. Krieg A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27 (2008) 161-167
7. Link B.K., Ballas Z.K., Weisdorf D., Wooldridge J.E., Bossler A.D., and Shannon M. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29 (2006) 558-568
8. Pashenkov M., Goess G., Wagner C., Hormann M., Jandl T., Moser A., Britten C.M., Smolle J., Koller S., Mauch C., Tantcheva-Poor I., Grabbe S., Loquai C., Esser S., Franckson T., Schneeberger A., Haarmann C., Krieg A.M., Stingl G., and Wag S.N. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24 (2006) 5716-5724
9. Almeida A.J., and Alpar H.O. Nasal delivery of vaccines. J. Drug Target. 3 (1996) 455-467
10. Ugwoke M.I., Agu R.U., Verbeke N., and Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 57 (2005) 1640-1665
11. Moldoveanu Z., Homan L.L., Huang W.Q., Krieg A.M., and DNA C. a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16 (1998) 1216-1224
12. Gallichan W.S., Woolstencroft R.N., Guarasci T., McCluskie M.J., Davis H.L., and Rosenthal K.L. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166 (2001) 3451-3457
13. Choudhury B.K., Wild J.S., Alam R., Klinman D.M., Boldogh I., Dharajiya N., Mileski W.J., and Sur S. In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J. Immunol. 169 (2002) 5955-5961
14. Lysaght J., Jarnicki A.G., and Mills K.H.G. Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity. Cancer Immunol. Immunother. 56 (2007) 1367-1379
15. Zhao Q., Temsamani J., Zhou R.Z., and Agrawal S. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7 (1997) 495-502
16. Hashida M., Kawakami S., and Yamashita F. Lipid carrier systems for targeted drug and gene delivery. Chem. Pharm. Bull. 53 (2005) 871-880
17. Kuramoto Y., Kawakami S., Zhou S., Fukuda K., Yamashita F., and Hashida M. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. J. Control. Release 126 (2008) 274-280
18. Corbctt T.H., Griswold Jr. D.P., Robcrts B.J., Pcckham J.C., and Schabcl Jr. F.M. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays with a note on carcinogen structure. Cancer Res. 35 (1975) 2434-2439
19. Hyoudou K., Nishikawa M., Umeyama Y., Kabayashi Y., Yamashita F., and Hashida M. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin. Cancer Res. 10 (2004) 7685-7691
20. Kawakami S., Sato A., Nishikawa M., Yamashita F., and Hashida M. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther. 7 (2000) 292-299
21. Kuramoto Y., Nishikawa M., Hyoudou K., Yamashita F., and Hashida M. Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. J. Control. Release 115 (2006) 226-233
22. Kawakami S., Higuchi Y., and Hashida M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J. Pharm. Sci. 97 (2008) 726-745
23. Huang L., and Li S. Liposomal gene delivery: a complex package. Nat Biotechnol. 15 (1997) 620-621
24. Chaudhry U.I., Kingham T.P., Plitas G., Katz S.C., Raab J.R., and DeMatteo R.P. Combined stimulation with Interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-γ and inhibit tumor growth. Cancer Res. 66 (2006) 10497-10504
25. Garcia-Santana M.A., Duconge J., Sarmiento M.E., Lanio-Ruiz M.E., Becquer M.A., Izquierdo L., and Acosta-Dominguez A. Biodistribution of liposome-entrapped human gamma-globulin. Biopharm. Drug Dispos. 27 (2006) 275-283
26. Suzuki K., Suda T., Naito T., Ide K., Chida K., and Nakamura H. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am. J. Respir. Crit. Care Med. 171 (2005) 707-713
27. Chen L., Arora M., Yarlagadda M., Oriss T.B., Krishnamoorthy N., Ray A., and Ray P. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide. J. Immunol. 177 (2006) 2373-2383
28. Loisel S., Gall C.L., Doucet L., Ferec C., and Flock V. Contribution on plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum. Gene Ther. 12 (2001) 685-696